MYNZ

Mainz Biomed N.V. (MYNZ) | Rumor.io

Mainz Biomed

MYNZ

Attention (50-day avg)0%

Attention rank (50-day avg)#4,864

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.51

Market capitalization17.1M

Earnings per share-5.28

Dividend yield (TTM)—

Revenue (annual)537.1K

Net income (annual)-16.2M

Social

What share of all stock conversation is about MYNZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% -0.01

Mar 11

Mainz Biomed B.V. (MYNZ) has appointed Robert Liscouski as Chairman of its Board of Directors, bringing over 35 years of experience in government, security strategy, and technology leadership.
The appointment is seen as a major credibility boost for the company, with some analysts expecting a 200% upside in the stock price.
The company is also planning to change its name to Quantum Cyber and its Nasdaq ticker symbol to QUCY, effective March 12.

Generated by AI

Sentiment

Of the messages about MYNZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.61% +21.39
Bearish	—	—	—	2.39% -21.39

Bullish· Mar 11

Mainz Biomed B.V. ($MYNZ) has strengthened its board with Robert Liscouski, a former senior U.S. government infrastructure protection leader, bringing credibility and leadership experience.
The company's leadership upgrade, including the appointment of Robert Liscouski as Chairman, has attracted new investor attention and is expected to change how investors look at Mainz Biomed overnight.
Mainz Biomed's strategic repositioning, including a shift toward Quantum Cyber positioning and a future ticker change to $QUCY, has added serious credibility to the board and is expected to attract fast trader interest and potentially lead to a 200% setup.

Bearish· Apr 29

Mainz Biomed B.V. ($MYNZ) has significant cash flow issues, with $6M in cash and $6M in liabilities, resulting in a -$22 EPS.
The company's stock price is heavily influenced by spamming and promotional activities on various boards, which has contributed to its decline.
The company's financial situation is precarious, with rumors of an overnight offering and under $500,000 in the bank, making it a high-risk investment.

Generated by AI

Topics

Of the messages about MYNZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	91.67%
Analysts	0%	0%	0%	0.04%
Controversies	0%	0%	0%	0.03%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	8.26%

Earnings· Jan 19

Mainz Biomed B.V.'s (MYNZ) third quarter fiscal year 2022 conference call and webcast has been scheduled.
No further information is available about the call's date or details.
The focus of the post is on the call's announcement rather than the earnings themselves.

Analysts· Apr 28

Mainz Biomed B.V. (MYNZ) is mentioned in a post that highlights Warren Buffett's purchase of STZ stock, but does not provide further information about MYNZ.
There is no additional information about Mainz Biomed B.V. (MYNZ) in the provided post.
The post does not provide any market-relevant information about Mainz Biomed B.V. (MYNZ).

Announcements· Mar 11

Mainz Biomed B.V. (MYNZ) appointed Robert Liscouski as Chairman of the Board, bringing 35+ years of experience in government, security strategy, and technology leadership.
The company plans to change its name to Quantum Cyber and its Nasdaq ticker symbol to QUCY, effective March 12.
MYNZ has secured a $6.0M private placement in two $3.0M tranches, with the first tranche already closed, providing fresh capital to support execution and extend runway.

Macro· Apr 28

Mainz Biomed's stock (MYNZ) has been mentioned in a sponsored segment, potentially indicating interest from a prominent investor.
Mainz Biomed's stock price and performance are not directly discussed, but the company's focus on cancer diagnostics and therapeutics is implied.
The post's focus on Warren Buffett's investment decision may have implications for the broader market, particularly in the biotech sector.

Technical Analysis· Nov 10

Mainz Biomed (MYNZ) is a diagnostics company focused on early cancer detection, with its lead product, ColoAlert, being sold through partner labs in Europe and targeting the US market with a feasibility study in 2025 and a pivotal PMA study in 2026.
The trading plan for MYNZ involves letting the first 15-30 minutes set the range, with a measured starter being reasonable if the first pullback forms a higher low and volume holds, and reassessing the setup if a capital raise is printed.
The fundamental backdrop for MYNZ has not changed, with EU commercialization continuing, a US feasibility read targeted for Q4 2025, and a pivotal study planned for 2026 subject to execution and funding, and tape quality is the filter for determining sustained revaluation.

Generated by AI

Community

Of the messages about MYNZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	64.69%
Newcomers	100%	100%	100%	35.31%

Regulars· Nov 13

Analysts are setting a $14 price target for MYNZ, implying a 90% discount to fair value, which some see as a miscalculation.
Institutions, including 16 funds, have accumulated nearly 400K shares of MYNZ before earnings, indicating they believe the downside is gone and the upside is huge.
The company's strong revenue growth, high gross margin, and progress in cancer diagnostics have caught the attention of traders, with the stock up 24% and showing momentum.

Newcomers· Mar 11

The appointment of Robert Liscouski as Chairman of Mainz Biomed B.V. ($MYNZ) has been met with significant market attention, with premarket trading already reaching $0.99 and $1.06.
The company's strategic shift toward Quantum Cyber positioning, including a planned ticker change to $QUCY, is seen as a major catalyst for the stock's momentum, with some traders expecting a 200% setup if momentum keeps building.
With a tight float of only ~7.5M shares, the stock's recent move is being attributed to the structure of the company, with some traders noting that microcaps with tight supply can experience significant price movements.

Generated by AI

News

Mainz Biomed to Attend 2025 Maxim Growth Summit

Mainz Biomed N.V. to Attend 2025 Maxim Growth Summit...

1mo agoBarchart.com

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025...

1mo agoBarchart.com

Also Discussed

Investors talking about MYNZ also mention

#	Name	Attention
1	MicroCloud Hologram Inc.HOLO	0%0
2	EXAS - Exact Sciences Corporation	——
3	Thermo Fisher Scientific Inc.TMO	0%0
4	Quest Diagnostics IncorporatedDGX	0%0
5	Bright Minds Biosciences Inc.DRUG	0%new
6	Bolt Biotherapeutics, Inc.BOLT	0%0
7	Ambev S.A. ADRABEV	0%0
8	Guardant Health Inc.GH	0%-0.11
9	Banco Bradesco S.A. ADRBBD	0.01%+0.01
10	Itaú Unibanco Holding S.A. ADRITUB	0%0

Mainz Biomed N.V.

Healthcare
Diagnostics & Research

Mainz Biomed N.V. is a biotechnology company primarily engaged in the development and commercialization of innovative diagnostic solutions. Headquartered in Mainz, Germany, this dynamic firm is dedicated to the advancement of early cancer detection technologies. Its flagship product focuses on non-invasive cancer screening, which significantly enhances the ability to detect the disease in its initial stages, thus allowing for timely intervention and better patient outcomes. Mainz Biomed operates within the healthcare sector, specifically impacting the diagnostics industry, where there is a continuous demand for precision medicine and effective diagnostic tools. The company plays a notable role in the market by leveraging cutting-edge genetic and genomic testing methodologies, contributing to the broader goal of improving cancer diagnostics. By operating at the intersection of biotechnology and healthcare, Mainz Biomed serves as a pivotal force in advancing medical technology aimed at transforming patient care through early and accurate diagnosis.

Website

Location

Robert Koch Strasse 50

Mainz, 55129

Germany

Social

What share of all stock conversation is about MYNZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% -0.01

Mar 11

Mainz Biomed B.V. (MYNZ) has appointed Robert Liscouski as Chairman of its Board of Directors, bringing over 35 years of experience in government, security strategy, and technology leadership.
The appointment is seen as a major credibility boost for the company, with some analysts expecting a 200% upside in the stock price.
The company is also planning to change its name to Quantum Cyber and its Nasdaq ticker symbol to QUCY, effective March 12.

Generated by AI

Sentiment

Of the messages about MYNZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.61% +21.39
Bearish	—	—	—	2.39% -21.39

Bullish· Mar 11

Mainz Biomed B.V. ($MYNZ) has strengthened its board with Robert Liscouski, a former senior U.S. government infrastructure protection leader, bringing credibility and leadership experience.
The company's leadership upgrade, including the appointment of Robert Liscouski as Chairman, has attracted new investor attention and is expected to change how investors look at Mainz Biomed overnight.
Mainz Biomed's strategic repositioning, including a shift toward Quantum Cyber positioning and a future ticker change to $QUCY, has added serious credibility to the board and is expected to attract fast trader interest and potentially lead to a 200% setup.

Bearish· Apr 29

Mainz Biomed B.V. ($MYNZ) has significant cash flow issues, with $6M in cash and $6M in liabilities, resulting in a -$22 EPS.
The company's stock price is heavily influenced by spamming and promotional activities on various boards, which has contributed to its decline.
The company's financial situation is precarious, with rumors of an overnight offering and under $500,000 in the bank, making it a high-risk investment.

Generated by AI

Topics

Of the messages about MYNZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	91.67%
Analysts	0%	0%	0%	0.04%
Controversies	0%	0%	0%	0.03%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	8.26%

Earnings· Jan 19

Mainz Biomed B.V.'s (MYNZ) third quarter fiscal year 2022 conference call and webcast has been scheduled.
No further information is available about the call's date or details.
The focus of the post is on the call's announcement rather than the earnings themselves.

Analysts· Apr 28

Mainz Biomed B.V. (MYNZ) is mentioned in a post that highlights Warren Buffett's purchase of STZ stock, but does not provide further information about MYNZ.
There is no additional information about Mainz Biomed B.V. (MYNZ) in the provided post.
The post does not provide any market-relevant information about Mainz Biomed B.V. (MYNZ).

Announcements· Mar 11

Mainz Biomed B.V. (MYNZ) appointed Robert Liscouski as Chairman of the Board, bringing 35+ years of experience in government, security strategy, and technology leadership.
The company plans to change its name to Quantum Cyber and its Nasdaq ticker symbol to QUCY, effective March 12.
MYNZ has secured a $6.0M private placement in two $3.0M tranches, with the first tranche already closed, providing fresh capital to support execution and extend runway.

Macro· Apr 28

Mainz Biomed's stock (MYNZ) has been mentioned in a sponsored segment, potentially indicating interest from a prominent investor.
Mainz Biomed's stock price and performance are not directly discussed, but the company's focus on cancer diagnostics and therapeutics is implied.
The post's focus on Warren Buffett's investment decision may have implications for the broader market, particularly in the biotech sector.

Technical Analysis· Nov 10

Mainz Biomed (MYNZ) is a diagnostics company focused on early cancer detection, with its lead product, ColoAlert, being sold through partner labs in Europe and targeting the US market with a feasibility study in 2025 and a pivotal PMA study in 2026.
The trading plan for MYNZ involves letting the first 15-30 minutes set the range, with a measured starter being reasonable if the first pullback forms a higher low and volume holds, and reassessing the setup if a capital raise is printed.
The fundamental backdrop for MYNZ has not changed, with EU commercialization continuing, a US feasibility read targeted for Q4 2025, and a pivotal study planned for 2026 subject to execution and funding, and tape quality is the filter for determining sustained revaluation.

Generated by AI

Community

Of the messages about MYNZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	64.69%
Newcomers	100%	100%	100%	35.31%

Regulars· Nov 13

Analysts are setting a $14 price target for MYNZ, implying a 90% discount to fair value, which some see as a miscalculation.
Institutions, including 16 funds, have accumulated nearly 400K shares of MYNZ before earnings, indicating they believe the downside is gone and the upside is huge.
The company's strong revenue growth, high gross margin, and progress in cancer diagnostics have caught the attention of traders, with the stock up 24% and showing momentum.

Newcomers· Mar 11

The appointment of Robert Liscouski as Chairman of Mainz Biomed B.V. ($MYNZ) has been met with significant market attention, with premarket trading already reaching $0.99 and $1.06.
The company's strategic shift toward Quantum Cyber positioning, including a planned ticker change to $QUCY, is seen as a major catalyst for the stock's momentum, with some traders expecting a 200% setup if momentum keeps building.
With a tight float of only ~7.5M shares, the stock's recent move is being attributed to the structure of the company, with some traders noting that microcaps with tight supply can experience significant price movements.

Generated by AI

Mainz Biomed

Social

Mar 11

Bullish· Mar 11

Bearish· Apr 29

Earnings· Jan 19

Analysts· Apr 28

Announcements· Mar 11

Macro· Apr 28

Technical Analysis· Nov 10

Regulars· Nov 13

Newcomers· Mar 11

Mainz Biomed to Attend 2025 Maxim Growth Summit

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Also Discussed

Mainz Biomed N.V.

Company Information

Location

Social

Mar 11

Bullish· Mar 11

Bearish· Apr 29

Earnings· Jan 19

Analysts· Apr 28

Announcements· Mar 11

Macro· Apr 28

Technical Analysis· Nov 10

Regulars· Nov 13

Newcomers· Mar 11

Mainz Biomed to Attend 2025 Maxim Growth Summit

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Also Discussed